Does retatrutide preserve muscle or cause muscle loss? What DXA body-composition data show, how it compares with tirzepatide, and what is still unknown.
PeptIQ Team
Peptide Research & Education
PeptIQ app
Track your peptide protocols in PeptIQ
Log injections, vial supply, and reminders. Use peptiq.io calculators when you need math on the web.
Under 25? Talk to a licensed clinician and get baseline labs before starting anything. Why we say this · Labs checklist
TL;DR
No published trial shows that retatrutide preserves muscle better than tirzepatide, and none shows that people build muscle on it. The best direct evidence is a Lilly-funded body-composition substudy of a phase 2 trial in adults with type 2 diabetes. Retatrutide reduced fat mass far more than placebo, and the authors reported that the share of weight lost as lean mass was similar to other obesity treatments, not lower.
For comparison, a body-composition substudy of tirzepatide's SURMOUNT-1 trial found that about 75% of the weight lost was fat and 25% was lean mass. The registered phase 3 trial comparing retatrutide directly with tirzepatide lists body weight as its primary outcome and no body-composition measures. Claims that retatrutide is "muscle-sparing" are therefore ahead of the data.
This PeptIQ.io guide reviews what was actually measured. Updated November 3, 2026. It contains no dosing information. Retatrutide is investigational and not FDA-approved.
Talk to a licensed clinician before starting, stopping or changing any weight-loss treatment.
Why Muscle Loss Is the Question Everyone Asks
Whenever body weight falls, some of the loss is fat and some is lean mass. That is true with diet, surgery and medicines. Newer incretin drugs produce larger weight loss than older options, so the absolute amount of lean mass lost can be larger too. That is why searches such as "does reta preserve muscle" and "retatrutide vs tirzepatide muscle loss" have grown alongside the trials.
A 2026 review in Diabetes & Metabolism Journal describes the shift well. The clinical focus is moving from the quantity of weight loss to its quality. The authors note that lean mass reduction is frequently observed with GLP-1 medicines, dual agonists and emerging multi-agonists.
Lean Mass Is Not the Same as Muscle
Most trial results come from DXA (dual-energy X-ray absorptiometry). DXA splits the body into fat, bone and "lean" tissue. Lean tissue includes skeletal muscle. It also includes water, organs and connective tissue.
So a falling lean-mass number does not mean the same amount of contractile muscle was lost. The same 2026 review states that loss of lean body mass does not necessarily indicate an equivalent loss of skeletal muscle or sarcopenia. It also describes possible improvements in muscle quality, because less fat builds up inside muscle.
The review also sets the outcomes that matter: strength, physical performance, falls, fractures and quality of life. It found no obvious functional harm in the available evidence. It cautions that long-term data are limited, especially for people with low muscle reserve.
PeptIQ.io / Retatrutide & muscle / 01
“Lean mass” is more than muscle.
DXA scans sort the body into fat, bone and lean tissue. A drop in lean mass is not automatically the same drop in muscle.
Skeletal muscle
The tissue people mean when they say “muscle.”
Water
Body water held in tissue is counted as lean.
Organs
Liver, heart, gut and other non-fat tissue.
Connective tissue
Tendon, ligament and other structural tissue.
What actually matters
StrengthPhysical performanceFalls & fracturesQuality of life
Measured, not marketed.Nov 2026
Schematic, not to scale; tiles do not show proportions. Source: Kim & Kim, Diabetes Metab J 2026 (PubMed 42722378). No dosing information.
What the Retatrutide Body-Composition Study Measured
The key paper is a 2025 substudy in The Lancet Diabetes & Endocrinology by Coskun and colleagues. It used a phase 2 trial in adults with type 2 diabetes at 42 U.S. centers. The comparison groups were placebo and dulaglutide, an older GLP-1 medicine. Tirzepatide was not included.
Who: 189 participants entered the body-composition substudy. 103 completed treatment with DXA scans at baseline and week 36.
Primary outcome: percent change in total fat mass at 36 weeks.
Fat mass: fell by up to about 26% in the higher-dose retatrutide groups, compared with about 4.5% on placebo and 2.6% on dulaglutide.
Lean mass: the authors concluded that the proportion of weight lost as lean mass was similar to other obesity treatments. They wrote that this offers reassurance that a greater proportion of lean mass is not lost, despite the larger weight loss.
Funding: the study was funded by Eli Lilly, and the listed authors are Lilly employees.
Read that conclusion carefully. "Not worse than other treatments" is a different claim from "preserves muscle better." The study did not measure strength or physical function. With 103 completers spread across several groups, it was not designed to rank drugs against each other.
What Tirzepatide's SURMOUNT-1 Scans Showed
For tirzepatide, the best comparison point is a 2025 SURMOUNT-1 body-composition analysis by Look and colleagues. In 160 adults with obesity or overweight, all scanned at baseline and week 72:
Body weight fell 21.3% on tirzepatide vs 5.3% on placebo.
Fat mass fell 33.9% vs 8.2%.
Lean mass fell 10.9% vs 2.6%.
About 75% of the weight lost was fat and 25% was lean mass, in both the tirzepatide and placebo groups. The split stayed fairly consistent across sex, age and the amount of weight lost.
The placebo comparison is the useful part. People losing weight on placebo, mostly with lifestyle advice, showed the same fat-to-lean split. On average, the medicine produced more weight loss with a similar composition, not a uniquely damaging one.
PeptIQ.io / Retatrutide & muscle / 02
Where the lost weight came from.
Share of total weight lost as fat vs lean mass. Tirzepatide and placebo showed the same split; retatrutide’s authors reported a share similar to other treatments.
Tirzepatide
SURMOUNT-1 DXA · 72 weeks
Fat ~75%
Lean ~25%
Weight −21.3% · Fat −33.9% · Lean −10.9%
Placebo
SURMOUNT-1 DXA · 72 weeks
Fat ~75%
Lean ~25%
Weight −5.3% · Fat −8.2% · Lean −2.6%
Retatrutide
Phase 2 DXA · T2D · 36 weeks
Reported as similar; exact split not in abstract
Fat mass down to about −26% in higher-dose groups vs −4.5% placebo
More weight lost, similar composition. That is not the same as “muscle-sparing.”
Measured, not marketed.Nov 2026
Different trials, populations and durations: do not compare rows as a head-to-head result. Sources: Look et al., Diabetes Obes Metab 2025 (PubMed 39996356); Coskun et al., Lancet Diabetes Endocrinol 2025 (PubMed 40609566).
Retatrutide vs Tirzepatide: Can You Compare Them?
Not reliably, yet. The two DXA studies differ in almost every way that matters:
Retatrutide substudy
Tirzepatide SURMOUNT-1 substudy
Participants
Adults with type 2 diabetes
Adults with obesity or overweight, without diabetes
Duration
36 weeks
72 weeks
Scanned completers
103
160
Comparator
Placebo and dulaglutide
Placebo
Author conclusion
Lean share similar to other obesity treatments
About 75% fat, 25% lean
Different populations, durations and analysis methods make side-by-side percentages misleading. The old version of this page claimed retatrutide preserves more muscle than tirzepatide. We removed that claim because no published head-to-head data support it.
A direct comparison is underway. ClinicalTrials.gov NCT06662383 is a phase 3, randomized, double-blind trial of retatrutide vs tirzepatide in about 800 adults with obesity. Its primary outcome is percent change in body weight. The listed secondary outcomes cover BMI, waist, lipids, blood pressure, HbA1c, fasting insulin and quality of life, but no body-composition measure. The registry shows estimated primary completion in November 2026. Even its results may not settle the muscle question.
What the Phase 3 Obesity Trial Adds
The first phase 3 obesity results were published in The New England Journal of Medicine in September 2026 (NCT05929066). The trial enrolled 2,339 adults with obesity and no diabetes for 80 weeks. Mean body-weight change was -17.6%, -23.7% and -25.0% across the three retatrutide groups, vs -3.9% with placebo. Knee osteoarthritis pain and sleep apnea events also improved in the participants who had those conditions.
The published abstract reports no body-composition data. Better knee-pain scores matter to people's lives. They are not a measure of muscle mass, though, and they should not be read as one.
A 2026 Pharmaceutics review of retatrutide makes the same point: the functional consequences of lean-mass loss still need further evaluation.
PeptIQ.io / Retatrutide & muscle / 03
What has been measured so far.
The muscle question has partial answers for fat and lean mass, and almost none for strength or function.
01
Retatrutide DXA
Coskun et al., 2025
Large fat loss; lean share similar to other obesity treatments. 103 scanned completers.
02
Tirzepatide DXA
Look et al., 2025
About 75% fat, 25% lean, the same split as placebo.
03
Phase 3 obesity
NEJM, Sept 2026
Weight, knee pain and sleep apnea improved. No body-composition data in the abstract.
04
Head-to-head
NCT06662383
Retatrutide vs tirzepatide. Primary outcome is body weight; no body-composition outcome listed.
05
Muscle function
Not reported
No published retatrutide trial result on strength or physical performance.
Measured, not marketed.Nov 2026
Evidence ladder as of November 3, 2026, from PubMed and ClinicalTrials.gov. Dashed rows mark gaps. Primary sources linked in the article.
"Can You Build Muscle on Retatrutide?"
No published retatrutide trial reports an average gain in lean or muscle mass. In the DXA data above, lean mass fell on average as people lost weight. Individual results vary, and resistance training changes the picture for many people, but that is not evidence that the drug builds muscle.
The mechanism story has the same gap. Retatrutide adds glucagon-receptor activity to GIP and GLP-1 activity. Some marketing claims glucagon activity protects muscle. We found no published human trial that tested that idea, so treat it as a hypothesis, not a result.
What Actually Has Support for Protecting Muscle
The review evidence points to unglamorous basics rather than a special molecule. The 2026 Diabetes & Metabolism Journal review recommends a "muscle-conscious" approach:
Body-composition assessment, not just the scale
Monitoring function, such as strength and everyday physical performance
Resistance training
Nutritional optimization, including adequate protein, set with a clinician or dietitian
Our peptides and muscle guide explains why no peptide "stack" has controlled-trial evidence for preventing lean-mass loss on GLP-1 medicines.
Regulatory Status in 2026
Retatrutide is investigational. FDA's page on unapproved GLP-1 drugs (content current as of October 1, 2026) states that retatrutide cannot be used in compounding under federal law. FDA has also warned companies that sold retatrutide labeled "for research purposes" or "not for human consumption." For the filing timeline and trial program, see what is retatrutide?.
Safety Questions to Raise With a Clinician
Given my age, strength and health history, how much lean-mass loss is acceptable for me?
Should I have a baseline body-composition scan, a strength test, or both?
What resistance-training and protein targets make sense for me?
Which signs, such as weakness, falls or slower recovery, should prompt a check-in?
Are there approved medicines with longer safety records that fit my situation?
How PeptIQ.io Helps
PeptIQ.io's health app sync can show weight and body-composition readings from Apple Health or Health Connect alongside your logged timeline. These are descriptive trends to discuss with your clinician, not a diagnosis. The Peptide Claim Auditor lets you submit a social post for an AI-assisted check against published research, which helps with "muscle-sparing" claims. The FDA status tracker summarizes regulatory status by compound.
Talk to a Licensed Clinician
Talk to a licensed clinician before using any weight-loss medicine, investigational or approved. Bring this guide's questions and ask how your muscle and function will be monitored, not only your weight.
Research supplier partner
Blank Peptides is a research-use-only supplier. Their listings are for laboratory / research use only — not for human consumption. Use code PEPTIQ for 10% off at checkout.
Visit Blank Peptides. Partner link. PeptIQ.io may earn a referral fee. Not medical advice.
Frequently Asked Questions
Q: Does retatrutide preserve muscle?
A: Not in the sense of preventing lean-mass loss. In the published DXA substudy, people lost far more fat than on placebo, and the authors reported that the share of weight lost as lean mass was similar to other obesity treatments. That is reassuring, but it is not proof of muscle sparing.
Q: Does retatrutide cause more muscle loss than tirzepatide?
A: No published head-to-head body-composition data answer this. The available DXA studies differ in population, duration and design. The registered retatrutide vs tirzepatide phase 3 trial lists body weight as its primary outcome and no body-composition measures.
Q: Can you build muscle on retatrutide?
A: No retatrutide trial reports average gains in lean or muscle mass. Lean mass fell on average in the DXA data. Resistance training and nutrition, guided by a clinician, have the strongest support for protecting muscle during weight loss.
Q: Is losing lean mass the same as losing muscle?
A: No. DXA lean mass includes water, organs and connective tissue as well as muscle. A 2026 review notes that lean-mass loss does not necessarily mean an equivalent loss of skeletal muscle. Strength and function are the outcomes that matter most.
Q: How much of the weight lost on tirzepatide is lean mass?
A: In the SURMOUNT-1 body-composition substudy, about 25% of the weight lost was lean mass and 75% was fat. The placebo group showed the same split.
Q: Is retatrutide FDA approved?
A: No. Retatrutide is investigational. FDA states it cannot be used in compounding under federal law and has warned sellers of retatrutide labeled for research use.
This article is educational content from PeptIQ.io. It is not medical advice. Talk with a licensed clinician before starting, stopping, or changing any peptide, medication, or injection practice.
For clinics: running peptide or GLP-1 programs for patients? See PeptIQ.io for providers: protocol templates, a patient app, and adherence tracking in one console.